Symbols / ENLV Stock $0.89 -2.01% Enlivex Ltd.

Healthcare • Biotechnology • Israel • NCM
ENLV (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Oren Hershkovitz Ph.D.
Exch · Country NCM · Israel
Market Cap 214.17M
Enterprise Value 205.80M
Income 1.24B
Sales —
FCF (ttm) -1.74B
Book/sh 8.15
Cash/sh 0.02
Employees 34
Insider 10d —
IPO Jul 31, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 0.03
Forward P/E -1.14
PEG —
P/S —
P/B 0.11
P/C —
EV/EBITDA -14.03
EV/Sales —
Quick Ratio 0.69
Current Ratio 193.24
Debt/Eq 0.03
LT Debt/Eq —
EPS (ttm) 25.48
EPS next Y -0.78
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-03-25
Earnings (prior) 2026-03-25
ROA -0.80%
ROE 126.17%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 241.05M
Shs Float 54.94M
Insider Own 86.58%
Instit Own 0.82%
Short Float 0.23%
Short Ratio 0.55
Short Interest 545.02K
52W High 2.10
vs 52W High -57.69%
52W Low 0.66
vs 52W Low 34.62%
Beta 1.68
Impl. Vol. 5.30%
Rel Volume 0.45
Avg Volume 575.47K
Volume 256.74K
Target (mean) $20.00
Tgt Median $20.00
Tgt Low $20.00
Tgt High $20.00
# Analysts 1
Recom Buy
Prev Close $0.91
Price $0.89
Change -2.01%
About

Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$20.00
Mean price target
2. Current target
$0.89
Latest analyst target
3. DCF / Fair value
$-129.71
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.89
Low
$20.00
High
$20.00
Mean
$20.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-07 main HC Wainwright & Co. Buy → Buy $20
2026-01-12 main HC Wainwright & Co. Buy → Buy $13
2025-11-24 down D. Boral Capital Buy → Hold —
2025-10-29 main D. Boral Capital Buy → Buy $13
2025-09-26 main D. Boral Capital Buy → Buy $13
2025-09-12 main D. Boral Capital Buy → Buy $13
2025-09-02 reit HC Wainwright & Co. Buy → Buy $7
2025-08-22 main D. Boral Capital Buy → Buy $13
2025-08-18 main D. Boral Capital Buy → Buy $13
2025-07-29 main D. Boral Capital Buy → Buy $13
2025-07-22 main D. Boral Capital Buy → Buy $13
2025-04-21 main D. Boral Capital Buy → Buy $13
2025-04-03 main D. Boral Capital Buy → Buy $13
2025-03-24 main HC Wainwright & Co. Buy → Buy $7
2025-03-03 main D. Boral Capital Buy → Buy $13
2025-02-07 main D. Boral Capital Buy → Buy $13
2024-12-11 main D. Boral Capital Buy → Buy $13
2024-12-03 main D. Boral Capital Buy → Buy $13
2024-11-14 main D. Boral Capital Buy → Buy $13
2024-09-27 reit HC Wainwright & Co. Buy → Buy $6
News
RSS: Latest ENLV news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
15.00
+0.46%
14.93
-40.63%
25.15
-2.50%
25.80
Research And Development
9.20
-13.36%
10.62
-44.12%
19.01
+1.71%
18.69
Selling General And Administration
5.68
+18.24%
4.81
-8.12%
5.23
-21.92%
6.70
General And Administrative Expense
5.68
+18.24%
4.81
-8.12%
5.23
-21.92%
6.70
Salaries And Wages
3.57
+11.83%
3.20
-0.93%
3.23
-15.24%
3.81
Other Gand A
1.83
+45.12%
1.26
-12.43%
1.44
-28.04%
2.00
Other Operating Expenses
0.11
+5.71%
0.10
-88.41%
0.91
+125.37%
0.40
Total Expenses
15.00
+0.46%
14.93
-40.63%
25.15
-2.50%
25.80
Operating Income
-15.00
-0.46%
-14.93
+40.63%
-25.15
+2.50%
-25.80
Total Operating Income As Reported
-15.03
+5.41%
-15.89
+45.95%
-29.39
-13.95%
-25.80
EBITDA
-14.67
-1.96%
-14.39
+40.84%
-24.32
+2.81%
-25.02
Normalized EBITDA
-1,647.06
-12333.48%
-13.25
+29.72%
-18.85
+0.46%
-18.94
Reconciled Depreciation
0.33
-39.08%
0.55
-34.73%
0.83
+7.46%
0.78
EBIT
-15.00
-0.46%
-14.93
+40.63%
-25.15
+2.50%
-25.80
Total Unusual Items
1,632.39
+143418.26%
-1.14
+79.17%
-5.47
+10.12%
-6.08
Total Unusual Items Excluding Goodwill
1,632.39
+143418.26%
-1.14
+79.17%
-5.47
+10.12%
-6.08
Special Income Charges
-0.03
+96.97%
-0.96
+77.45%
-4.24
0.00
Net Income
1,235.53
+8329.17%
-15.01
+48.35%
-29.07
+6.41%
-31.06
Pretax Income
1,618.17
+10877.77%
-15.01
+48.35%
-29.07
+6.41%
-31.06
Net Non Operating Interest Income Expense
0.78
-26.23%
1.06
-31.91%
1.55
+88.92%
0.82
Net Interest Income
0.78
-26.23%
1.06
-31.91%
1.55
+88.92%
0.82
Interest Income Non Operating
0.79
-25.91%
1.07
-31.69%
1.56
+87.43%
0.83
Interest Income
0.79
-25.91%
1.07
-31.69%
1.56
+87.43%
0.83
Other Income Expense
1,632.39
+143418.26%
-1.14
+79.17%
-5.47
+10.12%
-6.08
Gain On Sale Of Security
1,632.42
+897036.26%
-0.18
+85.13%
-1.22
+79.88%
-6.08
Tax Provision
382.65
0.00
0.00
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
386.06
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
1,235.53
+8329.17%
-15.01
+48.35%
-29.07
+6.41%
-31.06
Net Income From Continuing Operation Net Minority Interest
1,235.53
+8329.17%
-15.01
+48.35%
-29.07
+6.41%
-31.06
Net Income From Continuing And Discontinued Operation
1,235.53
+8329.17%
-15.01
+48.35%
-29.07
+6.41%
-31.06
Net Income Continuous Operations
1,235.53
+8329.17%
-15.01
+48.35%
-29.07
+6.41%
-31.06
Normalized Income
-10.81
+22.12%
-13.88
+41.21%
-23.60
+5.51%
-24.98
Net Income Common Stockholders
1,235.53
+8329.17%
-15.01
+48.35%
-29.07
+6.41%
-31.06
Diluted EPS
—
-0.73
+53.21%
-1.56
+7.69%
-1.69
Basic EPS
—
-0.73
+53.21%
-1.56
+7.69%
-1.69
Basic Average Shares
—
20.51
+10.44%
18.57
+0.98%
18.39
Diluted Average Shares
—
20.51
+10.44%
18.57
+0.98%
18.39
Diluted NI Availto Com Stockholders
1,235.53
+8329.17%
-15.01
+48.35%
-29.07
+6.41%
-31.06
Gain On Sale Of PPE
-0.03
+96.97%
-0.96
+77.45%
-4.24
0.00
Insurance And Claims
0.28
-19.94%
0.35
-38.10%
0.57
-36.65%
0.90
Other Taxes
0.00
+100.00%
-0.60
0.00
0.00
Total Other Finance Cost
0.01
+0.00%
0.01
-7.14%
0.01
+0.00%
0.01
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
2,327.00
+8304.66%
27.69
-24.83%
36.83
-45.55%
67.64
Current Assets
1,743.18
+6606.34%
25.99
-23.02%
33.76
-35.48%
52.33
Cash Cash Equivalents And Short Term Investments
5.75
-75.51%
23.50
-14.00%
27.32
-45.63%
50.24
Cash And Cash Equivalents
1.89
-42.62%
3.30
+306.03%
0.81
-98.37%
49.95
Cash Equivalents
0.31
-69.92%
1.04
0.00
-100.00%
47.82
Cash Financial
1.58
-30.00%
2.26
+177.61%
0.81
-61.71%
2.12
Other Short Term Investments
3.86
-80.88%
20.20
-23.81%
26.51
+8765.22%
0.30
Receivables
0.51
-63.96%
1.42
+517.90%
0.23
-64.61%
0.65
Accounts Receivable
—
—
—
—
Other Receivables
0.35
-74.16%
1.35
+1092.04%
0.11
-9.60%
0.12
Taxes Receivable
0.16
+138.24%
0.07
-41.38%
0.12
-77.78%
0.52
Prepaid Assets
3.85
+335.63%
0.88
-20.14%
1.11
-23.07%
1.44
Restricted Cash
—
—
—
0.11
Assets Held For Sale Current
0.00
-100.00%
0.20
-96.12%
5.11
0.00
Hedging Assets Current
1,708.79
0.00
—
—
Other Current Assets
24.27
—
—
—
Total Non Current Assets
583.82
+34363.99%
1.69
-44.77%
3.07
-79.97%
15.31
Net PPE
0.94
-18.65%
1.15
-55.31%
2.58
-82.68%
14.90
Gross PPE
4.78
-0.56%
4.80
-26.89%
6.57
-64.35%
18.43
Accumulated Depreciation
-3.84
-5.15%
-3.65
+8.52%
-3.99
-13.13%
-3.53
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.65
+10.75%
0.59
-0.85%
0.59
+12.57%
0.53
Other Properties
3.18
-2.75%
3.27
-28.10%
4.55
-51.08%
9.30
Leases
0.95
+0.00%
0.95
-33.82%
1.43
-83.37%
8.61
Investments And Advances
—
—
—
—
Other Investments
—
—
—
—
Non Current Accounts Receivable
—
0.21
—
—
Non Current Prepaid Assets
0.01
-55.56%
0.02
-90.37%
0.19
+65.49%
0.11
Other Non Current Assets
582.87
+183771.92%
0.32
+5.67%
0.30
+0.33%
0.30
Total Liabilities Net Minority Interest
392.05
+9466.86%
4.10
-39.26%
6.75
-37.53%
10.80
Current Liabilities
9.02
+137.46%
3.80
-37.32%
6.06
-8.26%
6.61
Payables And Accrued Expenses
6.04
+199.50%
2.02
-43.92%
3.59
-30.84%
5.20
Payables
3.81
+369.54%
0.81
-1.93%
0.83
-57.55%
1.95
Accounts Payable
3.81
+369.54%
0.81
-1.93%
0.83
-57.55%
1.95
Current Accrued Expenses
2.23
+84.97%
1.20
-56.47%
2.77
-14.81%
3.25
Pensionand Other Post Retirement Benefit Plans Current
2.73
+93.89%
1.41
+58.27%
0.89
+17.13%
0.76
Current Debt And Capital Lease Obligation
0.26
+9.79%
0.23
-32.08%
0.35
-47.01%
0.65
Current Capital Lease Obligation
0.26
+9.79%
0.23
-32.08%
0.35
-47.01%
0.65
Other Current Liabilities
—
0.14
-88.48%
1.23
—
Total Non Current Liabilities Net Minority Interest
383.03
+128003.34%
0.30
-56.41%
0.69
-83.64%
4.19
Long Term Debt And Capital Lease Obligation
0.38
+28.09%
0.30
-56.41%
0.69
-83.64%
4.19
Long Term Capital Lease Obligation
0.38
+28.09%
0.30
-56.41%
0.69
-83.64%
4.19
Non Current Deferred Liabilities
382.65
0.00
—
—
Non Current Deferred Taxes Liabilities
382.65
0.00
—
—
Other Non Current Liabilities
—
—
—
—
Stockholders Equity
1,934.95
+8102.76%
23.59
-21.59%
30.08
-47.07%
56.84
Common Stock Equity
1,934.95
+8102.76%
23.59
-21.59%
30.08
-47.07%
56.84
Capital Stock
28.73
+970.02%
2.69
+25.64%
2.14
+0.94%
2.12
Common Stock
28.73
+970.02%
2.69
+25.64%
2.14
+0.94%
2.12
Share Issued
237.38
+903.69%
23.65
+27.17%
18.60
+0.96%
18.42
Ordinary Shares Number
237.38
+903.69%
23.65
+27.17%
18.60
+0.96%
18.42
Additional Paid In Capital
796.70
+442.30%
146.91
+5.74%
138.94
+1.68%
136.65
Retained Earnings
1,108.42
+972.04%
-127.11
-13.39%
-112.09
-35.01%
-83.03
Gains Losses Not Affecting Retained Earnings
1.10
+0.00%
1.10
+0.00%
1.10
+0.00%
1.10
Other Equity Adjustments
1.10
+0.00%
1.10
+0.00%
1.10
—
Total Equity Gross Minority Interest
1,934.95
+8102.76%
23.59
-21.59%
30.08
-47.07%
56.84
Total Capitalization
1,934.95
+8102.76%
23.59
-21.59%
30.08
-47.07%
56.84
Working Capital
1,734.16
+7713.63%
22.19
-19.89%
27.70
-39.41%
45.72
Invested Capital
1,934.95
+8102.76%
23.59
-21.59%
30.08
-47.07%
56.84
Total Debt
0.64
+20.04%
0.53
-48.26%
1.03
-78.71%
4.85
Capital Lease Obligations
0.64
+20.04%
0.53
-48.26%
1.03
-78.71%
4.85
Net Tangible Assets
1,934.95
+8102.76%
23.59
-21.59%
30.08
-47.07%
56.84
Tangible Book Value
1,934.95
+8102.76%
23.59
-21.59%
30.08
-47.07%
56.84
Dueto Related Parties Current
—
—
—
—
Foreign Currency Translation Adjustments
—
—
1.10
+0.00%
1.10
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-10.42
+19.93%
-13.01
+44.70%
-23.52
+1.80%
-23.95
Cash Flow From Continuing Operating Activities
-10.42
+19.93%
-13.01
+44.70%
-23.52
+1.80%
-23.95
Net Income From Continuing Operations
1,235.53
+8329.17%
-15.01
+48.35%
-29.07
+6.41%
-31.06
Depreciation Amortization Depletion
0.33
-39.08%
0.55
-34.73%
0.83
+7.46%
0.78
Depreciation
0.33
-39.08%
0.55
-34.73%
0.83
+7.46%
0.78
Depreciation And Amortization
0.33
-39.08%
0.55
-34.73%
0.83
+7.46%
0.78
Other Non Cash Items
0.26
-11.45%
0.30
-57.33%
0.70
-16.25%
0.83
Pension And Employee Benefit Expense
—
—
—
—
Stock Based Compensation
1.78
-13.66%
2.06
+5.84%
1.95
-28.06%
2.71
Deferred Tax
382.65
0.00
0.00
—
Deferred Income Tax
382.65
0.00
0.00
—
Operating Gains Losses
-0.51
-260.25%
0.32
-91.83%
3.88
+95.71%
1.98
Gain Loss On Investment Securities
-0.54
+3.94%
-0.56
-62.68%
-0.34
-117.30%
1.98
Unrealized Gain Loss On Investment Securities
-1,631.28
0.00
0.00
—
Gain Loss On Sale Of PPE
-0.00
+98.78%
-0.08
-310.00%
-0.02
—
Change In Working Capital
0.81
+166.91%
-1.22
+33.00%
-1.82
-326.12%
0.80
Change In Prepaid Assets
-3.05
-804.62%
0.43
-28.78%
0.61
+118.71%
0.28
Change In Payables And Accrued Expense
4.07
+484.15%
-1.06
+27.94%
-1.47
-179.43%
1.85
Change In Accrued Expense
1.07
+202.97%
-1.04
-198.29%
-0.35
-151.17%
0.68
Change In Payable
3.00
+18831.25%
-0.02
+98.57%
-1.12
-195.98%
1.17
Change In Account Payable
3.00
+18831.25%
-0.02
+98.57%
-1.12
-195.98%
1.17
Change In Other Current Liabilities
-0.21
+65.14%
-0.59
+38.12%
-0.95
+27.98%
-1.33
Investing Cash Flow
-1.32
-114.60%
9.06
+134.89%
-25.97
-141.53%
62.52
Cash Flow From Continuing Investing Activities
-1.32
-114.60%
9.06
+134.89%
-25.97
-141.53%
62.52
Net PPE Purchase And Sale
-0.07
-182.72%
0.08
+178.64%
-0.10
+98.73%
-8.12
Purchase Of PPE
-0.07
+33.98%
-0.10
+56.36%
-0.24
+97.09%
-8.12
Sale Of PPE
0.00
-99.46%
0.18
+38.35%
0.13
0.00
Capital Expenditure
-0.07
+33.98%
-0.10
+56.36%
-0.24
+97.09%
-8.12
Net Investment Purchase And Sale
-1.26
-113.99%
8.98
+134.71%
-25.86
-136.61%
70.65
Purchase Of Investment
-44.00
-35.92%
-32.37
-23.71%
-26.17
-1272.10%
-1.91
Sale Of Investment
42.74
+3.37%
41.35
+13636.88%
0.30
-99.59%
72.55
Financing Cash Flow
10.38
+60.85%
6.45
+1692.78%
0.36
+140.00%
0.15
Cash Flow From Continuing Financing Activities
10.38
+60.85%
6.45
+1692.78%
0.36
+140.00%
0.15
Net Common Stock Issuance
10.38
+60.90%
6.45
+1692.22%
0.36
0.00
Proceeds From Stock Option Exercised
0.00
-100.00%
0.00
0.00
-100.00%
0.15
Changes In Cash
-1.36
-154.21%
2.50
+105.10%
-49.13
-226.88%
38.72
Effect Of Exchange Rate Changes
—
—
0.00
0.00
Beginning Cash Position
3.73
+204.32%
1.23
-97.57%
50.36
+332.77%
11.64
End Cash Position
2.37
-36.40%
3.73
+204.32%
1.23
-97.57%
50.36
Free Cash Flow
-10.48
+20.04%
-13.11
+44.82%
-23.76
+25.93%
-32.08
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Common Stock Issuance
10.38
+60.90%
6.45
+1692.22%
0.36
0.00
Issuance Of Capital Stock
10.38
+60.90%
6.45
+1692.22%
0.36
0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category